Ashwagandha

The marketing portfolio is wider than the evidence portfolio.

Stress and anxiety are the strongest lane: several meta-analyses of randomized trials report lower perceived stress, anxiety scale scores, and cortisol over roughly 4 to 12 weeks. Real signal, modest trials, variable extracts.

Athletic performance is an emerging lane: small to moderate effects on VO₂max, power, or recovery in short trials, not transformative, and not every pre-workout label.

Testosterone and libido are the weakest commercial lane, where seller language runs furthest ahead. Some men report modest testosterone shifts, often alongside resistance training; psychogenic erectile dysfunction trials have been null. Sleep, thyroid, and metabolic endpoints are scattered. A "T-booster" bottle is not the same claim as a stress RCT.

Evidence attaches to a claim lane and a defined extract, not to the root name alone.

Stress-lane meta-analyses describe root extracts at defined doses over weeks. Athletic and hormonal meta-analyses exist but sit at different confidence levels. Products differ in root vs leaf content, withanolide standardization, and dose. "Ashwagandha" on a label does not guarantee the extract used in any one trial.

• Using stress-trial evidence to validate testosterone, libido, fertility, or athletic performance marketing
• Assuming every ashwagandha product matches a studied extract and dose
• Assuming a "T-booster" or gym supplement matches the extract from a published stress trial
• Treating OTC use as risk-free because trials reported only mild adverse events
• Replacing evaluated psychiatric care for moderate or severe anxiety or depression
• Ignoring liver symptoms because the herb is "natural"

The useful first question is "Which claim lane?"

• Is the goal stress, sleep, energy, hormones, or something else?
• Which brand and dose are you taking, and for how long?
• Do you have liver disease, pregnancy plans, or thyroid condition?
• What other supplements or sedating medicines are you on?
• Have you noticed yellowing of eyes, abdominal pain, or unusual fatigue?

Liver case reports belong in the conversation even when trials look mild.

Trials often report mild digestive effects. Separately, case reports describe clinically apparent liver injury, usually cholestatic or mixed patterns, weeks after starting commercial products. Injury is uncommon relative to widespread use but serious cases occur, especially with pre-existing liver disease. Sedation, thyroid activity, and blood pressure shifts also deserve review with concurrent medicines.